Improving outcomes, reducing costs, and cutting readmissions are front and center for St. Jude Medical as it moves into new areas of cardio technology that suit the changing needs of both providers and patients.
A few weeks ago, St. Jude Medical Inc. marked the one-year anniversary of its acquisition of Atlanta, GA, company CardioMEMS Inc., developer of the CardioMEMS HF System, which became the first FDA-approved heart failure monitor that is proven to significantly reduce HF hospital admissions and improve quality of life in New York Heart Association (NYHA) class III patients.
To recap, the St Paul, MN, company took a 19% stake in CardioMEMS in 2010, and also took an option...
Leading industry experts have spoken to In Vivo about how investment, a change in mindset and a fresh approach to policy may allow Italy to kick-start its biotech ecosystem.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Against a backdrop of shifting trade policies, the end of multilateral market approaches and renewed focus on supply chain resilience, medtechs are doubling down on innovation in products and processes – using AI – and keeping unmet needs and outcomes in the center of the target.
The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.
Despite recent political turmoil, outside investor and corporate interest in South Korean biopharma innovation appears robust or even increasing.
Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.
